511,742 Shares in Novavax, Inc. $NVAX Purchased by Jump Financial LLC

Key Points

• Jump Financial LLC has acquired 511,742 shares of Novavax, Inc., valued at approximately $3.28 million, representing about 0.32% of the company's stock.
• Novavax's stock is currently trading at $7.52, with a market capitalization of $1.22 billion, and has experienced a 4.1% decline recently.
• The company reported an EPS of $0.62 for the last quarter, exceeding estimates, although its revenue is down 42.4% year-over-year.

Jump Financial LLC acquired a new position in Novavax, Inc. (NASDAQ:NVAX - Free Report) in the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 511,742 shares of the biopharmaceutical company's stock, valued at approximately $3,280,000. Jump Financial LLC owned approximately 0.32% of Novavax at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. GF Fund Management CO. LTD. purchased a new stake in Novavax in the 4th quarter worth about $27,000. Bank Julius Baer & Co. Ltd Zurich purchased a new stake in Novavax in the 1st quarter worth about $71,000. GAMMA Investing LLC lifted its stake in Novavax by 2,272.5% in the 1st quarter. GAMMA Investing LLC now owns 11,839 shares of the biopharmaceutical company's stock worth $76,000 after acquiring an additional 11,340 shares in the last quarter. Kitching Partners LLC purchased a new position in Novavax in the fourth quarter valued at about $89,000. Finally, Universal Beteiligungs und Servicegesellschaft mbH purchased a new position in Novavax in the first quarter valued at about $99,000. 53.04% of the stock is owned by hedge funds and other institutional investors.

Novavax Stock Down 4.1%

NVAX stock opened at $7.52 on Tuesday. The company has a debt-to-equity ratio of 5.93, a current ratio of 2.36 and a quick ratio of 2.34. The company has a 50-day moving average of $7.31 and a two-hundred day moving average of $7.17. The stock has a market capitalization of $1.22 billion, a price-to-earnings ratio of 3.30, a price-to-earnings-growth ratio of 0.10 and a beta of 2.50. Novavax, Inc. has a 52-week low of $5.01 and a 52-week high of $15.22.

Novavax (NASDAQ:NVAX - Get Free Report) last posted its quarterly earnings data on Wednesday, August 6th. The biopharmaceutical company reported $0.62 EPS for the quarter, topping analysts' consensus estimates of ($0.07) by $0.69. The business had revenue of $239.24 million for the quarter, compared to analyst estimates of $149.19 million. Novavax had a negative return on equity of 142.33% and a net margin of 39.20%.The firm's revenue for the quarter was down 42.4% on a year-over-year basis. During the same period in the previous year, the company posted $0.99 earnings per share. As a group, equities research analysts anticipate that Novavax, Inc. will post -1.46 EPS for the current year.

Wall Street Analysts Forecast Growth

NVAX has been the topic of a number of recent research reports. Citigroup initiated coverage on Novavax in a research note on Tuesday, June 17th. They issued a "sell" rating and a $6.00 target price on the stock. JPMorgan Chase & Co. lowered their target price on Novavax from $9.00 to $7.00 and set an "underweight" rating on the stock in a research note on Friday, May 9th. Bank of America restated an "underperform" rating and issued a $7.00 target price (down previously from $9.00) on shares of Novavax in a research note on Wednesday, August 20th. Finally, B. Riley restated a "buy" rating on shares of Novavax in a research note on Monday, May 19th. Four equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and three have given a Sell rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Hold" and a consensus target price of $15.57.

Novavax Profile

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.